• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study.

作者信息

Rankin Brian D, Georgakopoulos Jorge-Ryan, Sachdeva Muskaan, Mufti Asfandyar, Devani Alim R, Gooderham Melinda J, Hong Chih-Ho, Jain Vipul, Lansang Perla, Vender Ronald, Yeung Jensen, Prajapati Vimal H

机构信息

Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

出版信息

J Dermatolog Treat. 2022 Aug;33(5):2692-2694. doi: 10.1080/09546634.2022.2036673. Epub 2022 Apr 21.

DOI:10.1080/09546634.2022.2036673
PMID:35446185
Abstract
摘要

相似文献

1
Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study.度普利尤单抗治疗的特应性疾病患者中COVID-19的发病率和预后：一项多中心回顾性队列研究
J Dermatolog Treat. 2022 Aug;33(5):2692-2694. doi: 10.1080/09546634.2022.2036673. Epub 2022 Apr 21.
2
Letter to the editor submitted in response to 'Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study'.
J Dermatolog Treat. 2022 Nov;33(7):3066-3067. doi: 10.1080/09546634.2022.2089615. Epub 2022 Jun 20.
3
Safety of dupilumab in atopic patients during COVID-19 outbreak.在新冠疫情期间度普利尤单抗在特应性患者中的安全性。
J Dermatolog Treat. 2022 Feb;33(1):600-601. doi: 10.1080/09546634.2020.1771257. Epub 2020 Jun 19.
4
Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry.度普利尤单抗治疗特应性皮炎：来自捷克共和国BIOREP注册研究的真实世界数据。
J Dermatolog Treat. 2022 Aug;33(5):2578-2586. doi: 10.1080/09546634.2022.2043545. Epub 2022 Feb 21.
5
Real-life effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.度普利尤单抗在中度至重度特应性皮炎成年患者中的实际疗效和安全性。
Dermatol Ther. 2022 Jan;35(1):e15192. doi: 10.1111/dth.15192. Epub 2021 Nov 15.
6
Dupilumab ocular surface disease occurs predominantly in patients receiving dupilumab for atopic dermatitis: A multi-institution retrospective chart review.度普利尤单抗所致眼表疾病主要发生在接受度普利尤单抗治疗特应性皮炎的患者中：一项多机构回顾性病历审查。
J Am Acad Dermatol. 2021 Sep;85(3):735-736. doi: 10.1016/j.jaad.2019.07.031. Epub 2019 Jul 17.
7
Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy.青少年特应性皮炎：在意大利新冠疫情期间16周真实临床实践中使用度普利尤单抗的有效性和安全性
Dermatol Ther. 2021 Sep;34(5):e15035. doi: 10.1111/dth.15035. Epub 2021 Jun 25.
8
Prevalence of ocular disease during dupilumab treatment for atopic dermatitis: a bicentric retrospective comparative cohort study.特应性皮炎患者接受度普利尤单抗治疗期间眼部疾病的患病率：一项两中心回顾性对比队列研究。
Int J Dermatol. 2021 Dec;60(12):1520-1528. doi: 10.1111/ijd.15584. Epub 2021 May 26.
9
Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.成人中重度特应性皮炎患者使用度普利尤单抗的有效性和安全性的真实世界经验。
J Dermatolog Treat. 2021 Aug;32(5):507-513. doi: 10.1080/09546634.2019.1682503. Epub 2019 Oct 28.
10
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.度普利尤单抗治疗青少年中未得到控制的中重度特应性皮炎：一项 IIa 期开放标签试验及后续 III 期开放标签扩展研究的结果。
Br J Dermatol. 2020 Jan;182(1):85-96. doi: 10.1111/bjd.18476. Epub 2019 Oct 8.

引用本文的文献

1
Impact of COVID-19 pandemic on adults and children with atopic dermatitis and food allergy: Systematic review.2019年冠状病毒病大流行对特应性皮炎和食物过敏的成人及儿童的影响：系统评价
J Allergy Clin Immunol Glob. 2023 Oct 18;3(1):100181. doi: 10.1016/j.jacig.2023.100181. eCollection 2024 Feb.